39 2 CISPLATIN-INDUCED ACUTE KIDNEY INJURY | PART ONE Table 3. Renal function. Renal function, mean sCr, µmol/l (SD) Time point AKI Non-AKI p-value2 Baseline 66 (12) 65 (12) 0.78 3 months p-value1 103 (36) 0.001 79 (14) 0.01 0.001 12 months p-value1 100 (35) 0.002 80 (21) 0.01 0.01 Abbreviations: sCr, serum Creatinine; SD, Standard Deviation; p1, intra-group comparison of renal function to baseline sCr; p2, intergroup comparison of renal function Long-term renal function and treatment outcomes Data on sCr were available for all patients at baseline, for 108 patients (87%) at three months, and for 82 patients (66%) at twelve months post-treatment. There were no significant differences at baseline; mean sCr was 66 μmol/L (SD 12) for AKI patients, and 65 μmol/L (SD 12) for non-AKI patients (p= 0.78). At three months (Table 3), compared to baseline values, renal function was impaired in AKI patients (mean sCr c103 μmol/L, SD 36; p= 0.001), and also in non-AKI patients (mean sCr 79 μmol/L, SD 14; p= 0.01). At twelve months, compared to baseline values, renal function was impaired in both AKI patients (mean sCr 100 μmol/L, SD 35; p= 0.002), and non-AKI patients (mean sCr 80 μmol/L, SD 21; p= 0.01). Compared to non-AKI patients, renal function was significantly more impaired in AKI patients at three months (p= 0.01) and at twelve months (p= 0.01). Median follow-up time was 29 months (Interquartile Range, IQR 22-33) with no statistically significant difference between both groups. Disease recurrence rate was 25% in AKI patients, and 41% in non-AKI patients (OR 0.6, 95% CI 0.3-1.4; p= 0.22) (Figure 2). DSM rate was 19% in AKI patients, and 26% in non-AKI patients (OR 1.8; 95% CI 0.2-14.9; p= 0.61) (Figure 3).
RkJQdWJsaXNoZXIy MjY0ODMw